Tandem Diabetes Q2 Sales Reach $240.7mln, Missing Income Estimates

Tandem Diabetes reported Q2 sales of $240.7mln, missing income estimates. The company's sales rose compared to the previous year, but the financial results did not meet expectations.

Tandem Diabetes Care, Inc. (Nasdaq: TNDM) reported its financial results for the second quarter (Q2) 2025, showcasing an increase in sales compared to the previous year, but falling short of income estimates. The company reported worldwide sales of $240.7 million, a 9% increase from the $221.9 million recorded in the same quarter last year [1].

The company's Q2 2025 highlights include record sales in both the United States and internationally, a year-over-year and sequential gross margin improvement, and the initiation of an early access program for the t:slim X2™ insulin pump with Control-IQ+ technology integrated with Abbott’s FreeStyle Libre® 3 Plus continuous glucose monitoring sensor in the U.S. Additionally, the company received the CE Mark for the Tandem Mobi insulin delivery system with Control-IQ+ technology and completed a feasibility study to advance the development of a fully-closed loop automated insulin delivery system [1].

Despite these achievements, Tandem Diabetes Care reported a GAAP gross profit of $125.9 million, compared to $112.8 million in the same quarter last year. However, the GAAP operating loss was $51.8 million, or negative 22% of sales, compared to $30.8 million, or negative 14% of sales in Q2 2024. The non-GAAP operating loss was $31.9 million, or negative 13% of sales, compared to $30.9 million, or negative 14% of sales in Q2 2024 [1].

For the year ending December 31, 2025, Tandem Diabetes Care expects to reach $1 billion in worldwide sales, with sales in the United States estimated at approximately $700 million and sales outside the United States estimated at approximately $300 million. The company's adjusted EBITDA margin is being recast from approximately 3% to approximately negative 5% of sales for the full year [1].

The company's Q2 2025 results indicate that while Tandem Diabetes Care has shown growth in sales, the company is still facing significant financial challenges. The company's ability to achieve its projected financial results will be impacted by various risks and uncertainties, including market acceptance of its products, competition, changes in reimbursement rates, and operational challenges [1].

References:

[1] Tandem Diabetes Care, Inc. (2025). Tandem Diabetes Care, Inc. Reports Second Quarter 2025 Financial Results. Retrieved from https://www.stocktitan.net/news/TNDM/tandem-diabetes-care-announces-second-quarter-2025-financial-results-1vi3a9qlroup.html